Real-world evidence from engaged IBD cohorts

The gap in the evidence

Claims data tells you that a patient discontinued. It can't tell you whether it was driven by tolerability, cost, perceived non-response, access friction, or a payer switch. Registries are slow and expensive. Traditional PRO collection suffers from the same problem as every other patient touchpoint: attrition.

The result is that persistence, the single largest driver of real-world biologic value, is the outcome your organization has the least visibility into.

What Aidy captures

Because patients engage with Aidy through SMS as part of their day-to-day therapy support, data collection is longitudinal by default and doesn't decay the way app-based or survey-panel PRO collection does.

• Structured discontinuation drivers. A taxonomy of patient-reported reasons for stopping or considering stopping therapy (tolerability, cost and coverage, perceived efficacy, injection burden, life events), captured in the moment, not reconstructed at exit.

• Longitudinal PROs. Symptom trajectories, treatment burden, and quality-of-life measures collected on a cadence patients actually sustain.

• Persistence and adherence outcomes. Time-on-therapy curves, gap analysis, and re-initiation patterns tied to the patient-reported context around each event.

• Intervention response. What happens when a wavering patient gets timely support: the counterfactual your persistence business case is missing.

The fit for Medical Affairs

• Non-promotional by design. Aidy is a disease-support platform for IBD patients across therapies, a natural fit for medical, not commercial, sponsorship.

• Publication-grade rigor. Structured instruments, documented consent, IRB-ready protocols, and data governance built for peer review, not just dashboards.

• Fast time-to-signal. An already-growing IBD patient population means cohort accrual timelines measured in months, not years.

• Field medical relevance. Discontinuation-driver data gives MSLs something genuinely new to bring to KOL conversations about real-world persistence.

The dual-purpose case

Evidence generated with Aidy does double duty. The same persistence and discontinuation dataset that supports abstracts, publications, and HEOR models is exactly the evidence your Patient Services colleagues need to justify scaled support-program investment.